GlassScriptPhysician profile
Ali Altahir
NPI 1760506687
$3,471.40
in general payments reported to CMS, 2019-2025
19 companies · $1,627 in 2025
The $1,627 reported for 2025 was more than what 92% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $151 · 2022: $143 · 2023: $176 · 2024: $498 · 2025: $1,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $1,360 · Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $1,360.07 |
| Food and Beverage | $940.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,427.55 | 2019-2025 | Neurostar Tms Therapy System |
| Ironshore Pharmaceuticals INC. | $369.50 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $270.53 | 2019-2023 | Rexulti |
| Lundbeck LLC | $226.59 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $169.12 | 2023-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $154.05 | 2019-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $130.56 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $114.77 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $112.27 | 2019-2024 | Adzenys Xr-Odt |
| Abbvie INC. | $83.68 | 2022-2024 | Vraylar |
| Tris Pharma INC | $72.03 | 2019-2022 | |
| Adlon Therapeutics L.P. | $64.20 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $58.67 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.62 | 2019-2024 | Trintellix |
| Vertical Pharmaceuticals, LLC | $51.40 | 2019-2024 | Relexxii |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $50.05 | 2022-2025 | Azstarys |
| Shire North American Group INC | $22.60 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.08 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $19.13 | 2024 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Altahir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.